A safe place to talk about Crohn’s
Published in eyeforpharma April 2017 by Mariel Metcalfe
Anxiety and embarrassment are a vicious circle for people with Crohn’s disease. The psychological and emotional effects of this complex and often unrecognised condition not only dominate patients’ lives but raise the risk of further outbreaks.
Understanding and empathy around Crohn’s are in short supply. It is a relatively low-profile disease, with periods of remission broken by highly disruptive flare-ups. The very nature of those flare-ups tends to ensure that Crohn’s stays below the radar.
What next for the treatment of Psoriasis in Europe?
Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.
Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. A chronic autoimmune disease, psoriasis has an estimated prevalence of 2.5% in Europe, representing approximately 15 million people, with 20–25% of these suffering from severe disease.
Deep Dive: Using market research to facilitate patient centricity
Published in Pharmaphorum’s Deep Dive magazine March 2017
A number of factors have come together in recent years to drive a transformation within pharmaceutical companies from being product-led to patient-centric: An ever-growing and ageing global population is putting increasing pressure on healthcare systems, which need to decide how best to spend their limited budgets. Consequently, payers and policymakers are demanding clear demonstrations of real-world value and positive patient outcomes for new medicines. Physicians need support to make faster diagnoses and provision of treatments more tailored to individual patients. Patients, exposed to a wealth of information, are becoming more informed and engaged in decisions about how they are treated.
Making sense of Nutraceuticals in China
Published in eyeforpharma February 2017 by Marc Yates
The Chinese nutraceutical market is considered the third largest in the world after the US and Japan, or the fourth largest if Europe is counted as a single market. Despite strong fundamentals and high rates of annual growth, though, the Chinese market remains some way from realizing its true potential. Its evolution is muddied by ambiguities around what nutraceuticals actually are and how they should be managed. The result has been polarization between over-zealous regulation of so-called health foods, and a grey market where products have skirted approval procedures through questionable positioning or by exploiting alternative channels such as cross-border e-commerce.
Cool heads in a crisis?
Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics
First there was Ebola and now there is Zika; two official World Health Organization (WHO) Public Health Emergencies of International Concern (PHEIC) within as many years. Whenever global health crises such as these emerge, the pharmaceutical industry comes under intense scrutiny for not having an immediate solution available. Part of the problem is that prevention is not always financially viable; the substantial R&D costs of developing vaccines or treatments for all known and potential threats that may or may not one day develop into global pandemics is not a feasible burden for the industry to carry alone.